EVM
TAK icon

Eaton Vance Management’s Takeda Pharmaceutical TAK Stock Holding History

Eaton Vance Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,579
Closed -$424K – 1792
2022
Q1 		$424K Sell
29,579
-13,508
-31% -$198K ﹤0.01% 1557
2021
Q4 		$586K Buy
43,087
+1,830
+4% +$25.7K ﹤0.01% 1296
2021
Q3 		$585K Sell
41,257
-13,096
-24% -$220K ﹤0.01% 1190
2021
Q2 		$915K Sell
54,353
-7,724
-12% -$131K ﹤0.01% 1210
2021
Q1 		$1.13M Sell
62,077
-1,898
-3% -$34.1K ﹤0.01% 1108
2020
Q4 		$1.17M Buy
63,975
+7,421
+13% +$130K ﹤0.01% 1043
2020
Q3 		$1.01M Buy
56,554
+2,950
+6% +$53.7K ﹤0.01% 982
2020
Q2 		$961K Buy
53,604
+589
+1% +$10.6K ﹤0.01% 972
2020
Q1 		$811K Buy
53,015
+89
+0.2% +$1.61K ﹤0.01% 965
2019
Q4 		$1.04M Buy
52,926
+4,601
+10% +$88K ﹤0.01% 980
2019
Q3 		$831K Buy
48,325
+1,231
+3% +$21.3K ﹤0.01% 1015
2019
Q2 		$834K Sell
47,094
-10,245
-18% -$186K ﹤0.01% 1003
2019
Q1 		$1.17M Buy
+57,339
New +$1.15M ﹤0.01% 880

Other funds holding TAK

MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eaton Vance Management's TAK Position: Q2 2022 in Review

Eaton Vance Management sold out of Takeda Pharmaceutical (TAK) in Q2 2022, closing a stake of 29,579 shares — an estimated $424K sold.

Eaton Vance Management first reported a position in TAK in Q1 2019 and held it in 13 quarters. The position peaked at $1.17M in Q1 2019. 282 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

  • Eaton Vance Management reported no remaining Takeda Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 29,579 Takeda Pharmaceutical shares in Q2 2022, an estimated $424K.
  • Eaton Vance Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 13 quarters.
  • Eaton Vance Management's Takeda Pharmaceutical position peaked at $1.17M in Q1 2019.
  • 282 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.